TY - JOUR
T1 - Kidney transplantation without calcineurin inhibitors using sirolimus
AU - Stegall, Mark D.
AU - Larson, T. S.
AU - Prieto, M.
AU - Gloor, J.
AU - Textor, S.
AU - Nyberg, S.
AU - Sterioff, S.
AU - Ishitani, M.
AU - Griffin, M.
AU - Kremers, W.
AU - Lund, W.
AU - Schwab, T.
AU - Cosio, F.
AU - Velosa, J.
PY - 2003/5
Y1 - 2003/5
N2 - Introduction With the introduction of new immunosuppressive medicines, it has become possible to determine the extent to which nephrotoxic medicines contribute to CAN. The aim of this study is to compare the safety and efficacy of calcineurin inhibitor (CI) free immunosuppression in a prospective, randomized trial comparing sirolimus-mycophenolate mofetil (MMF)-prednisone to tacrolimus- MMF-prednisone. Methods Patients are randomized at the time of transplant to receive either tacrolimus (target level 12 to 15 ng/mL in the first month) or sirolimus (target level 12 to 18 ng/mL in the first month). All patients also receive MMF (750 mg bid) and prednisone tapered to 10 mg/d by 3 months and thymoglobulin induction (1.5 mg/kg/d on days 0, 1, 2, 4 and 6). Results At this point we have 4-month follow-up in 85 patients. The acute rejection rate is 7.5% (3/40) in the tacrolimus group and 6.7% (3/45) in the sirolimus group. We have discontinued sirolimus in eight patients so far, with wound complications being the most common indication. Renal function appears to be better in the sirolimus group at 1 month after transplantation, but the difference is not statistically significant. Conclusions While longer follow-up is needed, these results demonstrate that total avoidance of CI can be achieved with extremely low acute cellular rejection rates using sirolimus-based immunosuppression in combination with thymoglobulin, MMF, and prednisone.
AB - Introduction With the introduction of new immunosuppressive medicines, it has become possible to determine the extent to which nephrotoxic medicines contribute to CAN. The aim of this study is to compare the safety and efficacy of calcineurin inhibitor (CI) free immunosuppression in a prospective, randomized trial comparing sirolimus-mycophenolate mofetil (MMF)-prednisone to tacrolimus- MMF-prednisone. Methods Patients are randomized at the time of transplant to receive either tacrolimus (target level 12 to 15 ng/mL in the first month) or sirolimus (target level 12 to 18 ng/mL in the first month). All patients also receive MMF (750 mg bid) and prednisone tapered to 10 mg/d by 3 months and thymoglobulin induction (1.5 mg/kg/d on days 0, 1, 2, 4 and 6). Results At this point we have 4-month follow-up in 85 patients. The acute rejection rate is 7.5% (3/40) in the tacrolimus group and 6.7% (3/45) in the sirolimus group. We have discontinued sirolimus in eight patients so far, with wound complications being the most common indication. Renal function appears to be better in the sirolimus group at 1 month after transplantation, but the difference is not statistically significant. Conclusions While longer follow-up is needed, these results demonstrate that total avoidance of CI can be achieved with extremely low acute cellular rejection rates using sirolimus-based immunosuppression in combination with thymoglobulin, MMF, and prednisone.
UR - http://www.scopus.com/inward/record.url?scp=18544408129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18544408129&partnerID=8YFLogxK
U2 - 10.1016/S0041-1345(03)00226-4
DO - 10.1016/S0041-1345(03)00226-4
M3 - Article
C2 - 12742483
AN - SCOPUS:18544408129
SN - 0041-1345
VL - 35
SP - S125-S127
JO - Transplantation proceedings
JF - Transplantation proceedings
IS - 3 SUPPL.
ER -